An international phase III study, conducted in 1717 patients with metastatic castration-resistant prostate cancer, demonstrates that the use of a new drug, called enzalutamide, before chemotherapy reduces the risk of death caused by the disease and slows down its progression. In this group of patients the tumor does not respond to the hormonal therapies aimed at reducing the male hormones (androgens) that make cancer cells grow. This study demonstrated that the administration of enzalutamide before chemotherapy in patients with metastasis who rarely had symptoms, blocks these hormones, so the start of the chemotherapy can start until 28 months later. Researchers from the Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO) participated in this clinical trial, published in " "http://www.nejm.org/doi/full/10.1056/NEJMoa1405095?query=featured_home" The New England Journal of Medicine, that reduced by 81% the progression of the cancer, as compared with 14% among patients receiving placebo. Besides, the new drug is less toxic, with only side effects such as fatigue and hypertension.